Case Studies | BTC | Imfinzi

CASE STUDIES

UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA

Case study by Dr Nicholas Zdenkowski

Visiting Medical Officer, Medical Oncologist, Maitland Private Hospital, NSW

ADVANCED GALLBLADDER CANCER

Case study by Dr Rowan Doig

Medical Oncologist, Eastern Health and Epworth Centre, VIC

METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA

Case study by Dr Hieu Chau

Medical Oncologist, Latrobe Regional Hospital and Bairnsdale Regional Health Service, VIC

*Not the patient’s real name or image. Case studies have been adapted from a real clinical scenario.

MORE CASE STUDIES

Speak to an AstraZeneca representative about IMFINZI for BTC

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342.

PBS INFORMATION: Authority Required (STREAMLINED). Refer to PBS schedule for full information.

BTC, biliary tract cancer; gem-cis, gemcitabine-cisplatin.

References: 1. IMFINZI^® Approved Product Information.

IMFINZI^® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com.

Loading......

PBS Information: Authority required (STREAMLINED) for NSCLC. Refer to PBS Schedule for full authority information.

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AE: adverse event; BICR: Blinded Independent Central Review; CI: confidence interval; CRT: chemoradiation therapy; HR: hazard ratio; irAE: immune-related adverse event; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors.

References: 1. Girard N, et al. J Thorac Oncol 2023;18:181-193. 2. Spigel DR, et al. J Clin Oncol 2022;1301-1311. 3. Antonia SJ, et al. N Engl J Med 2017;377:1919-1929. IMFINZI® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. https://www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-15640 ASTR0828/EMBC Date of preparation: January 2023.